

Use of Antisense Oligonucleotides Against cPLA2 In the Treatment of Cancer (BGN)

code: Patent References: US 8,242,255; 8,735,368 IL 178764 EP 1758996 (Validated: Germany, France, UK)

[Rachel Levy](#), Department of Clinical Biochemistry, Faculty of Health Sciences, Ben-Gurion University and Soroka Medical Center, Beer Sheva, Israel

Contact for more information:

Ora Horovitz , Senior VP. Business Development,

BGN Technologies Ltd. - Technology Transfer Company of Ben-Gurion University, POB 653, Beer-Sheva, 84105, Israel. Tel: +972-8-6236949 Fax: +972-8-627-6420